New combo therapy shows promise for tough bone cancer

NCT ID NCT04803877

Ongoing Disease control Sponsor: Sarcoma Alliance for Research through Collaboration Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether combining two drugs, regorafenib and nivolumab, can help people with osteosarcoma (a type of bone cancer) that has returned or not responded to previous treatments. About 48 participants aged 5 and older will receive the combination. The main goal is to see if this approach improves the chance of living without the cancer growing for at least 4 months, compared to historical data with regorafenib alone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OSTEOSARCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

osteosarcoma pediatric osteosarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OSTEOSARCOMA OSTEOSARCOMA IN CHILDREN OSTEOSARCOMA METASTATIC OSTEOSARCOMA RECURRENT

Contacts and locations

Locations

Children's Hospital of Los Angeles

Los Angeles, California, 90027, United States
Cincinnati Children's

Cincinnati, Ohio, 45229, United States
Johns Hopkins

Baltimore, Maryland, 21287, United States
Oregon Health and Sciences University

Portland, Oregon, 97239, United States
UT Southwestern Medical Center

Dallas, Texas, 75390, United States
University of Miami

Miami, Florida, 33136, United States
University of Michigan

Ann Arbor, Michigan, 48109, United States
University of Minnesota

Minneapolis, Minnesota, 55455, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.